Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...1213141516171819202122...7475»
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Outbreak of Acute and Subacute Post-Injection Endophthalmitis caused by Pseudomonas aeruginosa (F0235) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_2888;    
    Important insights can be made into the atypical presentation and disease course to help guide future management. Unlike other cases of bacterial PIE, Pseudomonas persists within the eye despite intravitreal antibiotic injections with adequate coverage.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Ranibizumab and Regulation of Vascular Endothelial Cell Growth Factor Family Members in Patients with Diabetic Macular Edema (F0315) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_2764;    
    Ranibizumab treatment affected production of individual VEGF family members and altered specific pro-inflammatory signaling pathways that are seemingly linked to these differing VEGFs. Thus, new drug development focusing on targeting specific VEGF family members or, alternatively, the pro-inflammatory pathways connected to these family members could improve treatment of patients with diabetic macular edema and/or allow for a more personalized treatment approach.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Transformation of Subretinal Hyperreflective Material in Exudative Neovascular Age Related Macular Degeneration from Type 2 into Type 1 Appearance under anti-VEGF Therapy (F0175) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_2607;    
    Data for this post-hoc sub-analysis emerged from a 12-month, randomized, open label, multicenter study comparing the efficacy of Ranibizumab pro re nata versus Aflibercept bimonthly intravitreal injections in treatment-naïve patients newly diagnosed with exudative neovascular AMD (SALT)... Eyes with transformation of SHRM from type 2 into type 1 appearance on the course of therapy had a significantly higher mean improvement of visual acuity 3 and 12 months after initiation of therapy and showed a smaller area of decreased auto-fluorescence after 12 months.
  • ||||||||||  OPT-302 / Opthea, Lucentis (ranibizumab) / Roche, Novartis
    Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy ([Virtual]) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_2572;    
    P2
    OPT-302 combination therapy was well tolerated, with greater improvements in BCVA and less retinal fluid compared to ranibizumab monotherapy in participants with symptomatic macular PCV. Larger studies of dual inhibition of VEGF-C/-D and VEGF-A for the treatment of PCV are warranted.
  • ||||||||||  Vabysmo (faricimab) / Roche, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    RO-634 half-life as compared to published data on Aflibercept, Faricimab, Ranibizumab, and Bevacizumab. (F0111) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_2549;    
    Given RO-634’s excellent half-life and novel dual-inhibitory mechanism of action, we propose that this protein is a possible therapeutic candidate for exudative AMD, DME, and PDR. We are hopeful that future studies will continue to shed light on RO-634s safety and efficacy in both animal and human models.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    MFAP4 reduces vascular leakage in a Rabbit Model of Choroidal Neovascularization (CNV) (F0104) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_2541;    
    Using MFAP4 as alternative target to VEGF could be used as novel strategy, particularly in patients who respond poorly to anti-VEGF treatments. Layman Abstract: A proportion of patients with wet age related macular degeneeration do not respond, or stop responding, to treatemtn by intr-aocular injection of anti-VEGF agents like Lucentis or Eyelea.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Real-World Evidence (RWE) Registries () -  Apr 29, 2022 - Abstract #ARVO2022ARVO_2525;    
    Speakers Nicole Eter: Anti-VEGF treatment obtained in the OREGIS registry Daniel Barthelmes: 12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB!...The aim of the symposium is to show the possibilities of RWE registries for health services research. With the help of RWE registries prevalences and incidences of diseases can be shown, comorbidities can be identified and therapy regimens as well as long-term safety of therapeutics can be investigated.
  • ||||||||||  Vabysmo (faricimab) / Roche
    Angiopoietin-2 (Ang-2) signaling and vascular stability with faricimab in diabetic macular edema (DME) ([Virtual]) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_1295;    
    P2, P3
    Furthermore, dual Ang-2/VEGF-A blockade with faricimab promoted SRS in BOULEVARD and improved DME disease control in YOSEMITE/RHINE. These data support the role of Ang-2 in vascular stability and the potential for dual Ang-2/VEGF-A inhibition with faricimab to improve outcomes in patients with DME over anti-VEGF alone.
  • ||||||||||  RGX-314 / REGENXBIO, AbbVie
    Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE™ Study (205/207) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_842;    
    20 patients in Cohort 1 and 20 patients in Cohort 2 were randomized to receive RGX-314 at a dose level of 2.5x1011 and 5x1011 genomic copies per eye (GC/eye), respectively, versus monthly 0.5 mg ranibizumab intravitreal injection at a 3:1 ratio. Suprachoroidal RGX-314 has the potential to provide sustained clinical improvements in the treatment of nAMD with a one-time in-office treatment.
  • ||||||||||  Incidence Rates of Endophthalmitis after Various Pharmaceutical Intravitreal Injections (F0227) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_344;    
    This review suggests that TRIA yielded a significantly higher incidence rate of endophthalmitis as compared to the other medications. Layman Abstract: Rates of endophthalmitis, a serious vision-threatening condition, were compared based on the type of drug injected into the eye.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization. (Pubmed Central) -  Apr 26, 2022   
    Subconjunctival bevacizumab, ranibizumab, and aflibercept crossed the blood and seemed to be effective in inhibiting corneal neovascularization without causing epitheliopathy in an experimental rat model compared to the controls. However, no significant results were noted between these three anti-VEGF molecules.
  • ||||||||||  NN1213 / Novo Nordisk, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion date, Trial primary completion date:  Noctura400 Treatment for Diabetic Retinopathy (CANDLE) (clinicaltrials.gov) -  Apr 26, 2022   
    P=N/A,  N=252, Active, not recruiting, 
    However, no significant results were noted between these three anti-VEGF molecules. Trial completion date: Jul 2020 --> Sep 2022 | Trial primary completion date: Jul 2020 --> Sep 2022
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Age-Related Macular Degeneration and Diabetic Retinopathy. (Pubmed Central) -  Apr 24, 2022   
    Trial completion date: Jul 2020 --> Sep 2022 | Trial primary completion date: Jul 2020 --> Sep 2022 More than 15 years ago, the results of the pivotal trials supporting the intravitreal use of ranibizumab were published [...].
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Review:  Comparative Efficacy and Safety of Advanced Intravitreal Therapeutic Agents for Noninfectious Uveitis: A Systematic Review and Network Meta-Analysis. (Pubmed Central) -  Apr 23, 2022   
    Background: To compare the efficacy and safety of advanced intravitreal therapeutic regimens, including a dexamethasone implant at 350 and 700 μg; a fluocinolone acetonide (FA) implant, 0.2 µg/day, 0.59 and 2.1 mg; intravitreal bevacizumab, 1.25 mg; intravitreal ranibizumab, 0.5 mg; intravitreal triamcinolone acetonide (IVTA), 2 and 4 mg; and standard of care (SOC, systemic therapy) for noninfectious uveitis...IVTA, 4 mg, might be the best choice with lowest risk of IOP rising. Systematic Review Registration: clinicaltrials.gov, identifier CRD42020172953.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal, HEOR:  Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis. (Pubmed Central) -  Apr 20, 2022   
    This economic evaluation predominantly used data from the Center for Value-Based Medicine database to perform preference-based comparative effectiveness and cost-utility analyses for cataract surgery and intravitreal ranibizumab therapy for neovascular age-related macular degeneration (NVAMD) using vision utilities acquired from patients with ophthalmic disease (ophthalmic patient utilities) and from surrogate individuals (nonophthalmic patient vision utilities) with and without integrating systemic comorbidity utility limits on vision utility gain...Ophthalmologists should realize these phenomena and consider correcting the potential discrimination against disabled, elderly, and African American populations. This negative potential bias could theoretically result in beneficial intervention denial, less research dollars, curbed therapeutic advances, and decreased interventional reimbursement.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Macugen (pegaptanib) / Bausch Health
    Observational data, Retrospective data, Journal, HEOR:  Retrospective Analysis of the Pharmaco-Utilization of VEGF Inhibitors and Health Care Costs among Patients with Wet Age-Related Macular Degeneration and Other Ocular Diseases in Italy. (Pubmed Central) -  Apr 19, 2022   
    Across January 2010-December 2017, patients aged ≥50 years with a prescription of intravitreal anti-VEGFs were included as "wAMD" patients [by wAMD hospitalization or intravitreal injections] or as "other ocular diseases" patients [by hospitalization for other ocular disorders or intravitreal injections, with concomitant diabetes diagnosis or dexamethasone treatment]...Overall, 3879 patients were included; at index-date, 82.2% were treated with Ranibizumab, 15.8% with Aflibercept, and 2% with Pegaptanib...During the follow-up, the mean/annual anti-VEGF prescription [3.3 (first-year)-0.5 (third-year)] and the total cost [7196.83 € (first-year)-5162.68 € (third-year)] decreased. This observational study highlighted a decline in anti-VEGF prescriptions over time in both cohorts, suggesting a trend of under-treatment that could worsen the patients' clinical outcomes and increase health care resource consumption.